Kornimate/medical-research-clean huggingface dataset:
metabolic assessment of aging men with urinary lithiasis

Conditions: Urolithiasis and Aging; Renal Calcul and Metabolic Diseases; Urolithiasis and Osteoporosis

Summary: urinary lithiasis is a common disease on young adults, but not so far on aging people. nowadays, the investigators are seeing a gradative growth on men above sixty years old, mainly in industrialized countries. the purpose of this study is to investigate metabolic aspects of aging men with renal stones, towards blood tests, 24 hour-urinary samples, imagenological exams and bone densitometry. the investigators have made a case-control model.

urolithiasis is a common disease, with an overall prevalence about 2% in the world. accordingly growth of life expectancy, elderly people become more susceptible to present renal calculi. the investigators have two purposes: (1) evaluate metabolic disturbances in aging men with urinary lithiasis, and (2) evaluate bone demineralization in aging men with renal calculi. the investigators have made a case-control model. the case-group is compposed by men with more than fifty years-old who had their first lithiasic diagnosis (renal colic ou incidental finding) after that age. the control-group is compposed by men with more than fifty years-old who had never diagnosed with renal stones. so the investigators have excluded men with repetitive episodes of renal colic, that could be negatively influence the outcomes of aging factors on urinary lithiasis. all the people have to submitted to blood tests, 24-hour urinary samples, abdominal ultrassonography and abdominal x-ray (or abdominal ct, if necessary); and bone densitometry. the investigators hope to achieve reliable conclusions about urinary lithogenesis. blood tests: total calcium, ionized calcium, uric acid, phosphorus, creatinine, urea, testosterone and parathyroid hormone. 24-hour urinary sample(s): calcium, uric acid, creatinine, citrate, sodium, ph and volume. patients of the case arm had to collect 6 24-hour urine samples, while the control arm had collected 3 24-hour urine samples. data were analyzed using the fischer's exact, chi-square and mann-whitney tests; a level of significance of 5% was adopted.

Eligibility criteria:
inclusion criteria: * men above fifty years-old with urolithiasis diagnosis (case arm) * men above fifty years-old without urolithiasis diagnosis (control arm) exclusion criteria: * urolithiasis diagnosis (clinical or incidental) before fifty years-old. * urinary culture positive

Keywords: urolithiasis renal calculi aging osteoporosis
a study of switching to rpv plus other arvs in hiv-1-infected children (aged 2 to <12 years) who are virologically suppressed

Conditions: HIV

Summary: the purpose of this study is to evaluate the steady state pharmacokinetics (pk) of rilpivirine (rpv) and determine the appropriate dose of rpv in combination with other antiretrovirals (arvs) in participants aged greater than or equal to 2 to less than 12 years and to evaluate the safety and tolerability of rpv in combination with other arvs in participants of same age group over a 48-week treatment period with primary endpoint at week 24.

participants infected with human immunodeficiency virus type 1 (hiv-1) are routinely treated with combinations of multiple drugs which reduces hiv-1 ribonucleic acid (rna) to undetectable levels in a substantial proportion of participants and counteracts the risk of viral resistance development. rpv is a potent non-nucleoside reverse transcriptase inhibitor (nnrti) with in vitro activity against wild type (wt) hiv-1 and against nnrti-resistant hiv-1 mutants. a medical need still exists for the development of age/weight appropriate formulations in children less than (\<) 12 years of age. in this study, participants will switch to rpv plus other arvs. the primary analysis will be performed at week 24. a participant will be considered to have completed the study if he or she has completed assessments at week 48 of the study intervention phase. the total study duration for each participant, including screening and study intervention phases, will be approximately 54 weeks. key efficacy assessments include determination of plasma hiv-1 rna viral load and measurement of cd4+ cell count. key safety assessments will include the monitoring of (serious) adverse events (\[s\]aes) and hiv-related events, clinical laboratory tests, cardiovascular safety monitoring (vital signs and 12 lead electrocardiogram \[ecgs\]), and physical examination (including growth).

Eligibility criteria:
inclusion criteria: * weighing at least 10 kilogram (kg) at screening * have documented chronic human immunodeficiency virus (hiv-1) infection * on a stable antiretroviral (arv) regimen for at least 6 months prior to screening and virologically suppressed with documented evidence of at least 2 plasma viral loads less than (\<) 50 hiv-1 ribonucleic acid (rna) copies/milliliter (ml): one within 2-12 months prior to screening and one at screening * can switch from any arv class * never been treated with a therapeutic hiv vaccine * historical hiv-1 genotyping result at screening for children aged \>=2 to \ =6 to \<12 years if a historical hiv-1 genotyping result is available at screening) must demonstrate sensitivity to rpv and to the selected background arvs exclusion criteria: * have previously documented hiv-2 infection * have known or suspected acute (primary) hiv-1 infection * taken any disallowed concomitant therapies within 4 weeks before the planned first dose of study intervention * any current or history of adrenal disorder * a history of virologic failure to arvs with or without availability of an hiv-1 genotype result at the time of failure
implementation of smoking cessation support during lung cancer workup

Conditions: Suspected Lung Cancer

Summary: the aim of the present project is to implement smoking cessation support in hospital-based lung cancer workup. the effect on 1) patients' smoking cessation attempts, motivation, quality of life and psychosocial consequences of lung cancer workup as well as 2) hospitals' number of referrals to municipality-based smoking cessation programmes will be evaluated in a pragmatic, cluster-randomised controlled setup, where participating hospitals will be assigned to the intervention arm (implementation of smoking cessation support) or the control arm (usual practice). patients' and healthcare professionals' experiences with and barriers towards smoking cessation support will be explored in an interview-based, qualitative study.


Eligibility criteria:
inclusion criteria: * referred to lung cancer workup at participating hospital * able to speak and understand danish exclusion criteria: * unable to complete electronic questionnaires
probiotics for gallstones in post-bariatric surgery patients

Conditions: Bariatric Surgery Candidate; Gallstone; Gallstone Attack; Gastrointestinal Quality of Life Index; Probiotics

Summary: obesity is an increasing epidemic worldwide and has a significant impact on human health and socioeconomics. multiple studies have shown that bariatric surgery increases the risk of postoperative gallbladder stones. contributing factors to gallstone formation include gallbladder motility and bile supersaturation due to rapid weight loss and cholesterol mobilization. at present, the prevention and treatment of gallbladder stones in obese patients after bariatric surgery are still controversial. in recent years, the study of ursodeoxycholic acid in preventing gallbladder stone formation after bariatric surgery has become a research hotspot. at the same time, other studies have shown that taking probiotics or digestive enzymes may improve gastrointestinal symptoms and improve quality of life after bariatric surgery. therefore, the purpose of this study was to determine the ability of probiotics to prevent gallstone formation after bariatric surgery and to evaluate the impact of oral probiotics on quality of life in patients after bariatric surgery.


Eligibility criteria:
inclusion criteria: * patients receiving bariatric surgery for morbid obesity * patiets at ages between 20 to 60 y/o * patients willing to follow up regulary after bariatric surgery exclusion criteria: * patients having gallstones before bariatric surgery * patients refusing taking probiotics or refusing regular follow up after bariatric surgery

Keywords: bariatric surgery candidate gallstone probiotics
cinsarc genomic signature as predictor of resectability of ovarian adenocarcinoma

Conditions: Ovarian Adenocarcinoma

Summary: the majority of primary cancers of the ovary or peritoneum are represented by high-grade serous adenocarcinomas. these are rare pathologies, the incidence of which is estimated at 7.1 per 100,000, representing approximately 4,500 new cases per year in france (inca 2017). in the absence of effective screening, nearly 85% of patients have an advanced disease at diagnosis (corresponding to the figo iii or iva stage, characterized by diffuse peritoneal involvement). despite multidisciplinary care, the majority of patients (80%) will recur within a median of 18 to 24 months. it is therefore necessary to develop new tools, in particular molecular, in order to allow : * to better select patients accessible to full interval surgery * to exclude patients who would not benefit from this surgery in terms of survival in 2010, chibon et al. identified, from a cohort of patients with soft tissue sarcoma (stm), a molecular signature (called cinsarc), based on the expression profile of 67 genes involved in mitotic control and chromosomal integrity. the team showed that this transcriptomic signature is an independent prognostic factor in different types of stm, but also a prognostic factor more discriminating than the histological grade (fnclcc), historical and major prognostic factor of stm. being initially made from frozen material and on a dna biochip (affymetrix), this signature was unusable outside the field of fundamental research. this is why cinsarc has been gradually optimized, first by the rna sequencing technique on frozen tissue fixed in formalin (ffpe), and recently on ffpe tissue by the nanostring® technique. this very sensitive and inexpensive technique requires only small amounts of total rna, making it compatible with use on "routine" diagnostic samples, microbiopsy or surgical biopsy, opening the door to real clinical application. several clinical studies using this latest cinsarc optimization (called nanocind®) to determine the treatment of patients with stm will also begin soon. as a result of this work, necessary in order to more precisely support the potential of cinsarc in this pathology, the investigators hope to be able to assess from the diagnosis the evolutionary potential of the patients, which could make it possible to evaluate therapeutic strategies adapted to the profiles of each subpopulation: the investigators can for example imagine in theory a therapeutic de-escalation for low-risk patients, or else, for very high-risk patients, an intensified strategy.

rna extraction from 150 patients archival tumor, fragments of 50 to 300 nucleotides size. rna preparation, hybridation, detection, scanning according to nanostring manufacturer recommandations: obtention of cinsarc molecular signature sensibility, specificity, prognostic value of the signature will be analyzed

Eligibility criteria:
inclusion criteria: * patients with ovarian adenocarcinoma treated in iucto toulouse by primary chemotherapy and for whom diagnosis tumoral sample is available exclusion criteria: * none
observational study to evaluate the quality of life of healthy postmenopausal women who take coenzyme q-ubiquinol

Conditions: Health Status

Summary: observational study about quality of life in postmenopausal women taking coenzyme q compared to another group of women of the same age who do not take it

observational study to evaluate the subjective assessment performed by healthy postmenopausal women who are taking coenzyme q for 3 months, compared with other groups of the same characteristics that do not take it

Eligibility criteria:
inclusion criteria: * postmenopausal woman between 45 and 65 years old * woman who is taking coenzyme q-ubiquinol and who will continue taking at least the next 3 months * woman not taking coenzyme q-ubiquinol and not going to take it in the next 3 months exclusión criteria: * patients with severe mental illness. * suspicion or abuse of alcohol or other drugs during the 12 months prior to the selection * any other consideration or finding that, in the opinion of the investigator, considers the non-participation of the subject in the study.
partially covered versus uncovered pyloro-duodenal stents for unresectable malignant gastric outlet obstruction. a double blinded randomised controlled trial.

Conditions: Unresectable Malignant Gastric Outlet Obstruction

Summary: to compare the efficacy of a novel partially covered (pc) versus uncovered (uc) pyloro-duodenal stents (ds) in unresectable malignant gastric outlet obstruction. we hypothesize that the use of pcds could reduce the re-intervention rates when compared to ucds.

this would be a prospective multi-centred double-blinded randomised controlled study including all patients suffering from malignant gastric outlet obstruction due unresectable primary gastro-duodenal or pancreatico-biliary malignancies. five international institutions in hong kong, singapore and india would participate in the study. the procedure would be performed under conscious sedation or monitored anaesthesia. the patients would be randomised pcds or ucds after cannulation of the obstruction site is achieved with the guide-wire. the patients or assessors would be blinded to the type of stent that is inserted.

Eligibility criteria:
inclusion criteria: * consecutive patients ≥ 18 years old * confirmed unresectable gastro-duodenal or pancreatico-biliary malignancies * suffering from gastric outlet obstruction with a gastric outlet obstruction score of ≤ 1 (appendix 1) 19 * performance status ecog ≤3 (appendix 2) exclusion criteria: * prior metallic stent placement * severe comorbidities precluding the endoscopic procedure (such as cardiopulmonary disease, sepsis, or a bleeding disorder) * life expectancy of less than 1 month * history of gastric surgery * linitus plastica * coagulation disorders * pregnancy * unable to give informed consent

Keywords: unresectable malignant gastric outlet obstruction partially covered pyloro-duodenal stents uncovered pyloro-duodenal stents
effect of fu's subcutaneous needling on postoperative acute pain in patients with lumbar spine surgery.

Conditions: Pain, Postoperative

Summary: the goal of this clinical trial is to evaluate fu's subcutaneous needling (fsn) in postoperative pain in patients with lumbar spine surgery (lss). the main questions it aims to answer are: * is fsn effective for postoperative pain? * dose fsn decrease the tissue hardness after lss? * dose fsn have the effect of anti-inflammatory after lss? participants will receive routine analgesic and fsn after lss. researchers will compare sham group to see if fsn being effective for postoperative pain.


Eligibility criteria:
inclusion criteria: * pain and neurological symptoms are caused by degeneration of the spine (l1-s1) and require surgery. * one hour after lumbar spine surgery (evaluated after returning to the ward from the recovery room) visual analogue scale (vas) score ≥ 5 points * after being explained, join the trial voluntarily and sign the subject's consent form. exclusion criteria: * pain caused by acute trauma. * major diseases such as heart and lung failure, cancer, chronic kidney disease. * psychiatric disorder. * history of substance abuse. * a history of spinal surgery. * refused sign the consent form.

Keywords: fu's subcutaneous needling, postoperative pain
efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing multiple sclerosis.

Conditions: Relapsing Multiple Scelrosis

Summary: to compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis

this was a randomized, double-blind, double-dummy, active comparatorcontrolled, parallel-group, multi-center study with variable treatment duration in approximately 900 patients with relapsing multiple sclorosis (rms). the maximal treatment duration in the study for an individual patient was 2.5 years. eligible patients were randomized to receive either experimental ofatumumab subcutaneous (s.c.) injections every 4 weeks or active comparator teriflunomide orally once daily. the dose regimen for ofatumumab for this study was a loading dose regimen of 20 mg at day 1, day 7 and day 14, followed by a maintenance dose regimen of 20 mg administered every 4 weeks starting at week 4. in order to blind for the different formulations, double-dummy masking was used, i.e., all patients will take injections (containing either active ofatumumab or placebo) and oral capsules (containing either active teriflunomide or placebo).

Eligibility criteria:
inclusion criteria: * male or female patients aged 18 to 55 years at screening * diagnosis of multiple sclerosis (ms) * relapsing ms: relapsing-remitting ms (rrms) or secondary progressive ms (spms) with disease activity * documentation of at least: 1 relapse during the previous 1 year or 2 relapses during the previous 2 years or a positive gadolinium-enhancing mri scan during the year prior to randomization * disability status at screening with an expanded disability status scale (edss) score of 0 to 5.5 * neurologically stable within 1 month prior to randomization exclusion criteria: * patients with primary progressive ms or spms without disease activity * disease duration of more than 10 years in patients with an edss score of 2 or less * patients with an active chronic disease of the immune system other than ms * patients at risk of developing or having reactivation of hepatitis * patients with active systemic infections or with neurological findings consistent with pml

Keywords: relapsing multiple sclerosis ofatumumab adult omb157 multiple sclerosis t1 lesions t2 lesions relapse gd-enhancing mri mcdonald criteria rrms spms
isolation of pulmonary veins with the aid of magnetic resonance imaging

Conditions: Atrial Fibrillation

Summary: the alicia-fa study will elucidate whether targeting atrial myocardial fibrosis identified by late gadolinium-enhanced magnetic resonance imaging (lge-mri) improves atrial fibrillation (af) ablation outcomes.

atrial fibrosis is a hallmark of the af substrate. an accurate identification and localization of myocardial fibrosis areas prior to an ablation procedure by means of lge-mri might help to target atrial areas harboring af, thereby improving ablation outcomes and reducing af recurrences. in order to test this hypothesis, we will conduct a randomized study comparing the isolation of pulmonary veins without fibrosis imaging (conventional ablation procedure) vs. isolation of the pulmonary veins and pathological (fibrotic) tissue with the aid of lge-mri. fibrotic tissue patches will be encircled and isolated in all patients in the active arm; furthermore, lge-mri will be used to identify, locate and guide ablation catheter to anatomical gaps surrounding pulmonary veins in re-do procedures. eventually, we will identify an optimized ablation strategy in patients undergoing af radiofrequency ablation on the basis of left atrium (la) fibrosis characterization.

Eligibility criteria:
inclusion criteria: * patients undergoing a first or subsequent ablation procedure. * pre-procedural 3 tesla lge-mri. * referred for radiofrequency ablation of pulmonary veins (paroxysmal, persistent or long-standing af). * signed informed consent. exclusion criteria: * claustrophobia. * refusal to participate in the study. * presence of atrial thrombus. * la anteroposterior diameter \>55 mm. * major renal impairment. * contrast allergy. * pregnancy.

Keywords: catheter ablation radiofrequency fibrosis late-gadolinium enhanced mri
percutaneous gelled alcohol sclerotherapy for aggressive angiomas: evaluation of feasibility, safety, and efficacy

Conditions: Bone Angioma

Summary: the investigators aimed to evaluate efficacy and safety of a non-surgical protocol treatment combining transarterial embolization and percutaneous radiopaque gelled ethanol (rge) sclerotherapy in a first procedure, then followed by vertebroplasty in a second procedure, to treat aggressive vertebral hemangioma patients in tertiary hospital. exclusion criteria were age \<18-years old and any association with neurological deficit.


Eligibility criteria:
inclusion criteria: * every patients treated by gelled alcohol sclerotherapy for aggressive angiomas, in the university hospital of saint-etienne. exclusion criteria: * patients no treated by gelled alcohol sclerotherapy.

Keywords: percutaneous sclerosis ethanol gel aggressive bone angioma
covid-19 in a single large uk rheumatology centre and impact on qol

Conditions: Covid19; Rheumatic Diseases

Summary: the covid-19 pandemic represents a threat to rheumatology patients. national advice for patients to 'shield' is based on risk stratification of therapies and other risk factors. while the epidemiology of covid-19 in the rheumatological population is largely unknown large case registries are beginning to show potential drug treatment interactions. strict self-isolation (shielding) has been recommended for those deemed 'high risk' although its impact on the likelihood of covid-19 infection and health related quality of life (hrqol) is unclear. the study aims to explore how this unprecedented situation has impacted the trust patients primarily evaluating prevalence of the infection, effect of stringent social distancing (shielding) and quality of life (qol). this will be done via a voluntary questionnaire, sent via text messaging at 6 and 12 months.


Eligibility criteria:
inclusion criteria: * all rheumatology patients under active follow up at the royal wolverhampton trust with a validated mobile telephone number exclusion criteria: * patients without a validated mobile phone number linked to their hospital record